In contrast to the monotherapy by PD-1/PD-L1 inhibitors with few successes, combinatorial therapy of PD-1/PD-L1 antibodies with radiation therapy and/or chemotherapy seem more promising in the clinical trials against GBM. This evidence concerns the gene CD274 and glioblastoma.